Evidence map›Paper›PMID 37667046›Full record

ArticleAnnals of hematology2023

Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.

Qingya Wang, Zeyin Liang, Hanyun Ren, Yujun Dong, Yue Yin, Qingyun Wang, Wei Liu, Bingjie Wang, Na Han, Yangliu Li and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qingya Wang *Department of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Zeyin Liang *Department of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Hanyun RenDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Yujun DongDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Yue YinDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Qingyun WangDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Wei LiuDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Bingjie WangDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Na HanDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Yangliu LiDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China.
Yuan LiDepartment of Hematology, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, China. drliyuan75@163.com.

Funding

Beijing Natural Science Foundation 7202203National Natural Science Foundation of China 81970410Peking University First Hospital Scientific Research Seed Fund 2021SF13The Beijing Municipal Science and Technology Commission Z221100007422008
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a malignant lymphohematopoietic tumor that ranks among the most frequent indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT). This article aims to provide a comprehensive analysis of the application of allo-HSCT for AML and identify prognostic factors to enhance future treatment effect. This retrospective study collected data from 323 patients diagnosed with AML at Peking University First Hospital who underwent allo-HSCT between September 2003 and July 2022. The annual number of transplantations has steadily increased. Our center has observed a rise in the proportion of cytogenetic high-risk and measurable residual disease (MRD) positive patients since 2013, as well as an increase in the number of haploidentical transplantations. The overall leukocyte engraftment time has decreased over the past 20 years. Furthermore, both overall survival (OS) and disease-free survival (DFS) have significantly improved, while non-relapse mortality (NRM) has significantly decreased since 2013. Multivariate analysis identified transplantation before 2013, patients in complete remission (CR) 2 or non-CR, and recipients older than 50 years as risk factors for NRM, while patients in non-CR and patients with positive MRD are risk factors for recurrence. These findings offer insights into AML treatment outcomes in China, highlighting changes in transplantation practices and the need to reduce post-transplant relapse. Effective interventions, such as MRD monitoring and risk stratification schemes, are crucial for further enhancing transplant outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdolescentAdultAgedAllograftsChildChinaDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm, ResidualPrognosisRetrospective StudiesAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationRelapseSurvivalTransplantation practice

Identifiers

PMID37667046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.